secwatch.observer — SEC 8-K summary
======================================

Issuer:     Apogee Therapeutics, Inc. (APGE)
CIK:        0001974640
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001104659-26-001063
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Positive Phase 1b asthma data for zumilokibart; FeNO reduction 60%, durable to 32 weeks; 2026 milestones
--------------------------------------------------------------------------------

- Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.
- Favorable safety profile: no Grade ≥3 TEAEs, SAEs, conjunctivitis, injection site reactions, or anti-drug antibodies; TEAEs included GERD and upper respiratory infection.
- Positive trends in FEV1 and Type 2 biomarkers; further data to be presented at medical conferences.
- 2026 milestones: APEX Part A (AD, 52-week) data Q1; Part B (16-week) data Q2 (347 patients enrolled); Phase 3 AD start 2H 2026; APG279 vs DUPIXENT readout 2H 2026 (80 patients).
- Pro forma cash $913M as of Sept 30, 2025; cash runway into 2H 2028 supports advancement to potential 2029 launch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926001063/0001104659-26-001063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1974640/000110465926001063/tm261950d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer